Poseida Therapeutics, Inc. Shareholders' Equity
Poseida Therapeutics, Inc. had Shareholders' Equity of $87.21 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2024-11-07
- 2024-09-30: Stockholders' Equity Attributable to Parent $87.21M.
- 2024-06-30: Stockholders' Equity Attributable to Parent $60.82M.
- 2024-03-31: Stockholders' Equity Attributable to Parent $84.59M.
- 2023-12-31: Stockholders' Equity Attributable to Parent $103.70M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2024-09-30 | $87.21M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $60.82M 10-Q · filed 2024-11-07 | |
| 2024-03-31 | $84.59M 10-Q · filed 2024-11-07 | |
| 2023-12-31 | $103.70M 10-Q · filed 2024-11-07 | |
| 2023-09-30 | $123.66M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $135.30M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $157.56M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $187.59M 10-Q · filed 2024-11-07 | |
| 2022-09-30 | $216.31M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $65.80M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $103.70M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $156.21M 10-K · filed 2024-03-07 | |
| 2021-09-30 | $150.16M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $186.58M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $227.49M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $261.97M 10-Q · filed 2022-11-10 | |
| 2020-09-30 | $295.84M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$205.30M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | -$176.38M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $261.97M 10-K · filed 2023-03-09 | -$149.51M 10-Q · filed 2020-08-20 |
| 2019-09-30 | -$127.25M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$117.56M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | -$89.58M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | -$76.72M 10-K · filed 2021-03-11 |